Add-on Acquisition • Life Science

vivitide Acquires Peptides International

On December 16, 2019, vivitide acquired life science company Peptides International

Acquisition Context

This is vivitide’s 2nd transaction in the Life Science sector.
This is vivitide’s 2nd transaction in the United States.
This is vivitide’s 1st transaction in Kentucky.

Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	December 16, 2019
Target	Peptides International
Sector	Life Science
Buyer(s)	vivitide
Deal Type	Add-on Acquisition

Target Company

Peptides International

Louisville, Kentucky, United States

Peptides International, Inc. specializes in manufacturing and distributing high purity, biologically active peptides, enzyme substrates and inhibitors, innovative polymers and related products, and custom peptide synthesis services to life sciences and research institutions throughout the world. Peptides International, Inc. was founded in 1983 and based in Louisville, Kentucky.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

vivitide

Gardner, Massachusetts, United States

Category	Company
Founded	1998
Sector	Life Science

DESCRIPTION

vivitide is a provider of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. vivitide was founded in 1998 and is based in Gardner, Massachusetts.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	2 of 2
State: Kentucky	1 of 1
Country: United States	2 of 2
Year: 2019	1 of 1

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2008-01-01	Sigma-Genosys The Woodlands, Texas, United States Sigma-Genosys, a division of Sigma-Aldrich (NASDAQ:SIAL), sold its custom peptide and polyclonal antibody division to NEP, retaining its other product lines.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2008-01-01

Sigma-Genosys

The Woodlands, Texas, United States

Sigma-Genosys, a division of Sigma-Aldrich (NASDAQ:SIAL), sold its custom peptide and polyclonal antibody division to NEP, retaining its other product lines.

Buy

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Kentucky M&A - United States M&A - 2019 M&A